Global Medicines Program
DGH External Advisory Board Meeting

Andy Stergachis, PhD, Director
Professor of Epidemiology & Global Health
Adjunct Professor of Pharmacy & Health Services
stergach@uw.edu
www.globalmedicines.org

December 1, 2011
**Mission:**
Improve the use, safety, quality, risk-benefit profile, cost-effectiveness, and affordability of medicines in resource-poor countries.

**Objectives:**
1. Generate and disseminate new methods and knowledge on global medicines safety and value.
2. Teach and mentor graduate and professional students and practitioners in global medicines safety and value.
3. Strengthen pharmaceutical systems through research, capacity building, and global outreach.
Program Metrics

1. Recruit a senior fellow, junior faculty member, and research coordinator and establish the Program’s infrastructure.
2. Prepare and submit at least 4 manuscripts for publication and 3 applications for funding support annually.
3. Engage with key global stakeholders to offer 2 in-country training workshops/programs annually.
4. Update, expand, & offer interdisciplinary global medicines courses.
5. Establish inter- and intra-Departmental & School linkages and other key affiliations.
People: Global Medicines Program

Andy Stergachis, PhD
Director
Professor

Lou Garrison, PhD
Co-Director
Professor

Joseph Babigumira, MBChB, MS, PhD
Assistant Professor

Peggy Odegard, PharmD
Professor & Chair, Dept Pharmacy

Don Downing, BPharm
Clinical Professor of Pharmacy

Laura Sangaré, PhD, MPH
Senior Research Fellow

Becky Bartlein, MPH
Research Coordinator

Lou Garrison, PhD
Co-Director
Professor

Affiliated Faculty To-Date

Peggy Odegard, PharmD
Professor & Chair, Dept Pharmacy

Don Downing, BPharm
Clinical Professor of Pharmacy

Thomas Brewer, MD
Bill & Melinda Gates Foundation
UW Global Medicines Program is a core partner to MSH’s new Award from USAID

The UW Global Medicines Program is a core partner to a newly awarded cooperative agreement to Management Sciences for Health (MSH) by the US Agency for International Development (USAID). This a five-year $197.9 million Cooperative Agreement for the Systems for Improved Access to Pharmaceuticals and Services (SIAPS) Program follows the current Strengthening Pharmaceutical Systems (SPS) [...]"
Major Activities

1. Strengthening Pharmaceutical Systems-MSH via USAID
2. Pharmacovigilance via BMGF:
   - Strategy & Methods Development
   - Malaria in Pregnancy Consortium
3. Health Technology Assessment in Developing Countries and Emerging Markets
4. Cost-Effectiveness Analysis of Vaccines—Measles, Influenza, Pneumococcal
## Progress To-Date – Examples

<table>
<thead>
<tr>
<th>Producing Knowledge</th>
<th>Transmitting and Applying Knowledge</th>
</tr>
</thead>
<tbody>
<tr>
<td>20+ GMP-Related Manuscripts</td>
<td>4 PhDs awarded: Epidemiology &amp; Pharmacy</td>
</tr>
<tr>
<td></td>
<td>Global Pharmacovigilance Conference, 2010, Nairobi</td>
</tr>
<tr>
<td></td>
<td>International Society for Pharmacovigilance, Ghana, 2010</td>
</tr>
<tr>
<td></td>
<td>ICIUM Conference, Antalya, Turkey, 2011</td>
</tr>
<tr>
<td>30+ Global Medicines Presentations</td>
<td>“Global Health Pharmacy: Medicines, Practice, and Policy” Four (4) UW Courses</td>
</tr>
<tr>
<td></td>
<td>In-Country Training Workshops &amp; Technical Assistance: Namibia, Vietnam, Ethiopia, India</td>
</tr>
<tr>
<td></td>
<td>Cost and Outcomes in Health and Medicine Course</td>
</tr>
<tr>
<td></td>
<td>Affiliation in process with UNAM Pharmacy Degree Program</td>
</tr>
<tr>
<td></td>
<td>IOM Committee on Strengthening Core Elements of Regulatory Systems in Developing Countries</td>
</tr>
</tbody>
</table>
Intra-Departmental Linkages

- **ICRC** – Planning for results of trials
  - Acyclovir guidelines, procurement, access in SSA
  - PrEP pharmacovigilance concept paper
- **I-TECH** – Medication management/Systems strengthening
  - Collaborations where there’s geographical overlap, UNAM
  - HEAL-TB proposal
- **IHME** – Population-based medication use assessment
  - Participation in “A Novel Integrated Multi-source Surveillance System for Tracking Health Disparities”
- **KRP** – Joint mentorship of postdoctoral fellow
- **GBD** – Cost-effectiveness of RDT for malaria
What Have We Learned?

• **Strengths:**
  – Co-directors have well-established linkages within UW and with many relevant external organizations
  – Program initiated with a combination of DGH initiative funding and external grant and contract support
  – Demonstrated novel and efficient approaches to pharmacovigilance in LMIC

• **Weaknesses:**
  – Need to attract a larger core of interdisciplinary faculty with an interest in collaboration on global medicines issues
  – Limited resources
  – Strengthen metrics, especially impact
Future Directions

1. Hold a forum/meeting of faculty interested in affiliating with GMP
2. Establish an advisory committee
3. Plan for sustainability
4. Increase dissemination efforts
5. Formalize Program affiliations
6. Postmarketing surveillance with public-private partnerships
7. Geographical expansion in conjunction with DGH?
Vision Statement

• The “Center for Global Medicines” is a leader in research and training that promotes global access to safe and cost-effective medicines and pharmacy services to achieve improved and sustainable health and systems impact.
Key Questions

1. What important medicines-related global public health problems are we missing in our current and planned activities and direction?

2. What suggestions do you have to strengthen the dissemination and impact of our program activities?

www.globalmedicines.org